114 related articles for article (PubMed ID: 8558528)
1. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
[TBL] [Abstract][Full Text] [Related]
4. 1,4-Benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists.
Sherrill RG; Berman JM; Birkemo L; Croom DK; Dezube M; Ervin GN; Grizzle MK; James MK; Johnson MF; Queen KL; Rimele TJ; Vanmiddlesworth F; Sugg EE
Bioorg Med Chem Lett; 2001 May; 11(9):1145-8. PubMed ID: 11354363
[TBL] [Abstract][Full Text] [Related]
5. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
Dezube M; Sugg EE; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; James MK; Johnson MF; Mosher JT
J Med Chem; 1995 Aug; 38(17):3384-90. PubMed ID: 7650691
[TBL] [Abstract][Full Text] [Related]
6. 3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists.
Willson TM; Henke BR; Momtahen TM; Myers PL; Sugg EE; Unwalla RJ; Croom DK; Dougherty RW; Grizzle MK; Johnson MF; Queen KL; Rimele TJ; Yingling JD; James MK
J Med Chem; 1996 Jul; 39(15):3030-4. PubMed ID: 8709137
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents.
Pierson ME; Comstock JM; Simmons RD; Kaiser F; Julien R; Zongrone J; Rosamond JD
J Med Chem; 1997 Dec; 40(26):4302-7. PubMed ID: 9435899
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
Bellier B; McCort-Tranchepain I; Ducos B; Danascimento S; Meudal H; Noble F; Garbay C; Roques BP
J Med Chem; 1997 Nov; 40(24):3947-56. PubMed ID: 9397175
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
11. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.
Ghanekar D; Hadac EM; Holicky EL; Miller LJ
J Pharmacol Exp Ther; 1997 Sep; 282(3):1206-12. PubMed ID: 9316827
[TBL] [Abstract][Full Text] [Related]
12. 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.
Henke BR; Willson TM; Sugg EE; Croom DK; Dougherty RW; Queen KL; Birkemo LS; Ervin GN; Grizzle MK; Johnson MF; James MK
J Med Chem; 1996 Jul; 39(14):2655-8. PubMed ID: 8709093
[No Abstract] [Full Text] [Related]
13. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
Smeets RL; Fouraux MA; Pouwels W; van Emst-de Vries SE; Ronken E; De Pont JJ; Willems PH
Br J Pharmacol; 1998 Jul; 124(5):935-45. PubMed ID: 9692779
[TBL] [Abstract][Full Text] [Related]
15. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
[TBL] [Abstract][Full Text] [Related]
16. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
[TBL] [Abstract][Full Text] [Related]
17. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Tabuchi S; Nakanishi I; Satoh Y
Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
[TBL] [Abstract][Full Text] [Related]
18. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
[TBL] [Abstract][Full Text] [Related]
19. ARL 15849: a selective CCK-A agonist with anorectic activity in the rat and dog.
Simmons RD; Kaiser FC; Pierson ME; Rosamond JR
Pharmacol Biochem Behav; 1998 Feb; 59(2):439-44. PubMed ID: 9476993
[TBL] [Abstract][Full Text] [Related]
20. New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.
Makovec F; Chistè R; Bani M; Pacini MA; Setnikar I; Rovati LA
Arzneimittelforschung; 1985; 35(7):1048-51. PubMed ID: 4052139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
